Side-by-side · Research reference
GHK-CuvsHumanin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED8/47 cited
BAnimal-StrongHUMAN-REVIEWED14/52 cited
GHK-Cu
Tripeptide · Skin / Hair / Wound Healing
SQ or topical · Local · Daily or 2-3×/week
Humanin
Mitochondrial-Derived Peptide · Cytoprotective
SQ · Experimental
01Mechanism of Action
Parameter
GHK-Cu
Humanin
Primary target
Copper-dependent enzymes (lysyl oxidase, SOD); regulator of >4000 human genesPickart 2018
Pathway
Cu(II) delivery via GHK chelation → ↑collagen / elastin / GAG synthesis; ↓inflammatory cytokines; ↑hair follicle growth-factor signalingPickart 2018
Humanin binds Bax/Bim → inhibits mitochondrial outer membrane permeabilization (MOMP) → blocks cytochrome c release → prevents caspase activation → cell survival
Downstream effect
Skin firmness + texture improvement, accelerated wound healing, hair regrowth, anti-inflammatory actionPickart 2018Zink 2003
Suppression of apoptosis, mitochondrial stabilization, reduced oxidative stress, preservation of germ cells and neurons under stressZhu 2022Lue 2021Velentza 2024
Feedback intact?
Replaces declining endogenous levels
Not applicable — peptide acts as anti-apoptotic signal, not hormonal axis
Origin
Endogenous tripeptide first isolated from human plasma; declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60Pickart 2018
Encoded by short open reading frame in mitochondrial 16S rRNA gene (MTRNR2). 24-28 amino acids. 13 homologous variants (MTRNR2L1-L13) identified.Zhu 2022Shahzaib 2026
Antibody development
—
Not reported in animal models
02Dosage Protocols
Parameter
GHK-Cu
Humanin
Standard SQ dose
1–2 mg / dayPickart 2018
Anecdotal injectable range; topical creams use 0.1–2% solutions.
—
Topical concentration
0.1–2.0% in serum / cream
—
Frequency
Daily or 2–3× per week (SQ)
Daily (IP)
Lower / starter dose
0.5 mg / day SQ
—
Evidence basis
Human-mechanistic + topical clinical studiesPickart 2018
Animal models (rat, mouse)Huang 2025El 2022Velentza 2024
Duration
8–12 weeks for visible skin / hair effect
8–12 weeks in animal studies
Reconstitution
Bacteriostatic water; light-protected
—
Timing
No specific time; evening preferred for topicals
—
Half-life
Hours (estimated; rapid tissue uptake)
—
Standard experimental dose (HNG)
—
4 mg/kg IP (rat)
Most common dose in rodent models.
Ex vivo bone culture
—
1 µg/mL
Protective against venetoclax-induced bone growth retardation.
Human data
—
None — no clinical trials reported
Analog (HNG)
—
Gly[14]-humanin — more potent variant
Substitution at position 14 enhances cytoprotective activity.
03Metabolic / Fat Loss Evidence
Parameter
GHK-Cu
Humanin
Direct fat loss evidence
—
None
Mechanism overlap
—
Mitochondrial health may indirectly influence metabolic efficiency, but no quantified effect
04Side Effects & Safety
Parameter
GHK-Cu
Humanin
Injection site reaction
Erythema, mild pruritus (common)
Not reported in animal studies (IP route)
Topical irritation
Mild redness, transient stinging
—
Copper accumulation
Theoretical with very high chronic doses
—
Allergic reaction
Rare hypersensitivity to copper
—
Pregnancy / OB
Avoid topical and SQ — insufficient data
—
Wilson disease
Contraindicated
—
Animal model safety
—
Well-tolerated in rat and mouse studies at 4 mg/kg for 8–12 weeks
Human safety data
—
None — no clinical trials
Theoretical fibrillation risk
—
Induces amyloid-like fibrillation of Bax/BID. Long-term sequelae unknown.
Reproductive safety
—
Protective in POI model (cyclophosphamide-induced), no adverse effects on fertility notedHuang 2025
Absolute Contraindications
GHK-Cu
- ·Wilson disease (copper-overload disorder)
- ·Pregnancy / breastfeeding
- ·Known copper hypersensitivity
Humanin
- ·Unknown — no human data
Relative Contraindications
GHK-Cu
- ·Hemochromatosis (copper-iron crosstalk theoretical)
- ·Concurrent copper-chelator therapy
Humanin
- ·Active malignancy (theoretical risk of anti-apoptotic effect on tumour cells)
05Administration Protocol
Parameter
GHK-Cu
Humanin
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 50 mg vial → 25–50 mg/mL. Use within 30 days, refrigerated.
Intraperitoneal (IP) in animal models. Subcutaneous route untested. No human protocols exist.
2. Injection site
SQ — local to the area of interest (face, scalp) for skin / hair indications. Rotate sites.
Synthetic peptide reconstituted in sterile saline or PBS. No commercial formulation available.
3. Timing
Anytime; evening preferred. Topical: apply to clean dry skin.
Daily administration in animal studies. Optimal timing not characterized.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, light-protected, ≤30 days.
Lyophilised powder: -20 °C. Reconstituted: 4 °C, use within 7 days. Avoid freeze-thaw cycles.
5. Needle
30–31G, short (4–6 mm) for shallow SQ. Topical: clean fingertips, no needle.
No FDA approval, no IND, no clinical trials. Experimental research tool only.
06Stack Synergy
GHK-Cu
+ BPC-157
ModerateGHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.
- GHK-Cu
- 1–2 mg SQ · daily near wound
- BPC-157
- 250–500 mcg SQ · daily near wound
- Primary benefit
- Combined ECM rebuilding + angiogenesis for tissue repair
Humanin
+ MOTS-c
Multi-pathwayBoth are mitochondrial-derived peptides. MOTS-c enhances metabolic efficiency and insulin sensitivity via AMPK activation, while humanin prevents mitochondrial apoptosis. Combined, they address mitochondrial function (MOTS-c) and survival signaling (humanin), supporting cellular resilience under metabolic and oxidative stress.
- Humanin
- 4 mg/kg IP · daily (animal model)
- MOTS-c
- 5 mg/kg IP · daily (animal model)
- Frequency
- Once daily
- Primary benefit
- Mitochondrial health, metabolic efficiency, anti-apoptotic signaling